Global Surveillance and the Value of Information: The Case of the Global Polio Laboratory Network

Abstract

Effective control and eradication of diseases requires reliable information from surveillance activities, including laboratories, which typically incur real financial costs. This article presents data from a survey we conducted to estimate the costs of the Global Polio Laboratory Network (GPLN), which currently supports aggressive global surveillance for acute flaccid paralysis (AFP) to detect circulating polioviruses. The Global Polio Eradication Initiative (GPEI) of the World Health Organization (WHO) provides resources for some of the laboratory network costs, but the total cost of the network remains relatively poorly characterized given the limited documentation of national contributions. We surveyed network laboratories to quantify AFP surveillance support costs and provide data for cost estimates of potential posteradication surveillance policies related to the laboratories. We estimate that the GPLN currently requires millions (US dollars 2002) in total support annually, and that half of the support for national and regional reference laboratories comes from external donors through the WHO or bilateral agreements and half from within nations that host those laboratories. The article also presents the framework for considering the value of information from this global surveillance network and suggests that the expected value of surveillance information from the GPLN currently exceeds its costs. We also provided important insights about how the value of information may change after successful eradication of wild polioviruses.

Cost-Effectiveness of the Introduction of a Pre-Erythrocytic Malaria Vaccine into the Expanded Program on Immunization in Sub-Saharan Africa: Analysis of Uncertainties Using a Stochastic Individual-Based Simulation Model of Plasmodium falciparum Malaria

“…One specific aspect of these analyses of uncertainty is quantification of the value of acquiring additional information on these parameters by computing the theoretical value of complete information about them (expected value of perfect information, [EVPI] [9]). Although EVPI has only recently been applied in health sector evaluations relevant to low-and middle-income countries [10], this analysis is highly pertinent to decisions of whether to deploy RTS,S.…”

Preeradication Vaccine Policy Options for Poliovirus Infection and Disease Control

“…Dynamic disease and economic modeling helped national and global policymakers appreciate the strong economic justification for global polio eradication, (19,20) the reality that control is neither risk-nor cost-free, (21) and issues related to posteradication policies and decisions. (14)(15)(16)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31) Countries face increasing complexity as they select their poliovirus vaccine(s) for national use, particularly with the current availability of monovalent OPV (mOPV) and bivalent OPV (bOPV) formulations and changing formulations for inactivated poliovirus vaccine (IPV). Global discussions about OPV cessation options also impact national choices.…”

Public health requirements for rapid progress in global health

“…Exceptions, such as surveillance for acute flaccid paralysis as a marker for polio, as described by de Gourville et al (2006), demonstrate the enormous potential of such systems.…”